Platelet function and fibrinolytic agents: Two sides of a coin?

Kevin P. Callahan, Alex I. Malinin, Paul A. Gurbel, John H. Alexander, Christopher B. Granger, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

Fibrinolytic therapy is sthe established treatment for the management of patients with ST elevation acute myocardial infarction (AMI). Present fibrinolytic regimens have a number of shortcomings, including the failure to produce early and sustained reperfusion, as well as failure to prevent reocclusion in at least some patients. Platelets play an important role in coronary thrombosis responsible for AMI. The effect of coronary fibrinolysis on platelets has been extensively debated in the literature with evidence of both platelet activation and inhibition. Among fibrinolytic agents, tissue plasminogen activator (t-PA) is considered to be the mainstay in the treatment of coronary artery disease. The native t-PA molecule has been modified in an attempt to achieve improved lytic characteristics with less risk of bleeding. The result is a group of mutant t-PA variants considered third-generation plasminogen activators. TNK-t-PA is one bioengineered variant of t-PA. Another third-generation plasminogen activator is reteplase (r-PA). Like TNK-t-PA, it is a variant of t-PA that has been developed to establish a more rapid, complete, and stable coronary artery patency, thus promising reduced mortality. Both r-PA and TNK-t-PA are effective when given as bolus therapy. This feature may facilitate more rapid treatment as well as decrease overall costs of treatment. New fibrinolytic regimens include potent antiplatelet agents that may improve sustained reperfusion. This review summarizes the latest and often confusing data on the interaction between fibrinolytic therapy and platelets in certain in vitro, animal and clinical scenarios.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalCardiology
Volume95
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Numismatics
Fibrinolytic Agents
Tissue Plasminogen Activator
Blood Platelets
Plasminogen Activators
Thrombolytic Therapy
Reperfusion
Coronary Thrombosis
Platelet Aggregation Inhibitors
Platelet Activation
Fibrinolysis
Therapeutics
Health Care Costs
Coronary Artery Disease
Coronary Vessels
Myocardial Infarction
Hemorrhage
Mortality
TNK-tissue plasminogen activator

Keywords

  • Alteplase
  • Platelets
  • Reteplase
  • Streptokinase
  • Tenecteplase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Callahan, K. P., Malinin, A. I., Gurbel, P. A., Alexander, J. H., Granger, C. B., & Serebruany, V. L. (2001). Platelet function and fibrinolytic agents: Two sides of a coin? Cardiology, 95(2), 55-60. https://doi.org/10.1159/000047346

Platelet function and fibrinolytic agents : Two sides of a coin? / Callahan, Kevin P.; Malinin, Alex I.; Gurbel, Paul A.; Alexander, John H.; Granger, Christopher B.; Serebruany, Victor L.

In: Cardiology, Vol. 95, No. 2, 2001, p. 55-60.

Research output: Contribution to journalArticle

Callahan, KP, Malinin, AI, Gurbel, PA, Alexander, JH, Granger, CB & Serebruany, VL 2001, 'Platelet function and fibrinolytic agents: Two sides of a coin?', Cardiology, vol. 95, no. 2, pp. 55-60. https://doi.org/10.1159/000047346
Callahan KP, Malinin AI, Gurbel PA, Alexander JH, Granger CB, Serebruany VL. Platelet function and fibrinolytic agents: Two sides of a coin? Cardiology. 2001;95(2):55-60. https://doi.org/10.1159/000047346
Callahan, Kevin P. ; Malinin, Alex I. ; Gurbel, Paul A. ; Alexander, John H. ; Granger, Christopher B. ; Serebruany, Victor L. / Platelet function and fibrinolytic agents : Two sides of a coin?. In: Cardiology. 2001 ; Vol. 95, No. 2. pp. 55-60.
@article{7455d0c9c90942549a12bd9809ec7818,
title = "Platelet function and fibrinolytic agents: Two sides of a coin?",
abstract = "Fibrinolytic therapy is sthe established treatment for the management of patients with ST elevation acute myocardial infarction (AMI). Present fibrinolytic regimens have a number of shortcomings, including the failure to produce early and sustained reperfusion, as well as failure to prevent reocclusion in at least some patients. Platelets play an important role in coronary thrombosis responsible for AMI. The effect of coronary fibrinolysis on platelets has been extensively debated in the literature with evidence of both platelet activation and inhibition. Among fibrinolytic agents, tissue plasminogen activator (t-PA) is considered to be the mainstay in the treatment of coronary artery disease. The native t-PA molecule has been modified in an attempt to achieve improved lytic characteristics with less risk of bleeding. The result is a group of mutant t-PA variants considered third-generation plasminogen activators. TNK-t-PA is one bioengineered variant of t-PA. Another third-generation plasminogen activator is reteplase (r-PA). Like TNK-t-PA, it is a variant of t-PA that has been developed to establish a more rapid, complete, and stable coronary artery patency, thus promising reduced mortality. Both r-PA and TNK-t-PA are effective when given as bolus therapy. This feature may facilitate more rapid treatment as well as decrease overall costs of treatment. New fibrinolytic regimens include potent antiplatelet agents that may improve sustained reperfusion. This review summarizes the latest and often confusing data on the interaction between fibrinolytic therapy and platelets in certain in vitro, animal and clinical scenarios.",
keywords = "Alteplase, Platelets, Reteplase, Streptokinase, Tenecteplase",
author = "Callahan, {Kevin P.} and Malinin, {Alex I.} and Gurbel, {Paul A.} and Alexander, {John H.} and Granger, {Christopher B.} and Serebruany, {Victor L.}",
year = "2001",
doi = "10.1159/000047346",
language = "English (US)",
volume = "95",
pages = "55--60",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Platelet function and fibrinolytic agents

T2 - Two sides of a coin?

AU - Callahan, Kevin P.

AU - Malinin, Alex I.

AU - Gurbel, Paul A.

AU - Alexander, John H.

AU - Granger, Christopher B.

AU - Serebruany, Victor L.

PY - 2001

Y1 - 2001

N2 - Fibrinolytic therapy is sthe established treatment for the management of patients with ST elevation acute myocardial infarction (AMI). Present fibrinolytic regimens have a number of shortcomings, including the failure to produce early and sustained reperfusion, as well as failure to prevent reocclusion in at least some patients. Platelets play an important role in coronary thrombosis responsible for AMI. The effect of coronary fibrinolysis on platelets has been extensively debated in the literature with evidence of both platelet activation and inhibition. Among fibrinolytic agents, tissue plasminogen activator (t-PA) is considered to be the mainstay in the treatment of coronary artery disease. The native t-PA molecule has been modified in an attempt to achieve improved lytic characteristics with less risk of bleeding. The result is a group of mutant t-PA variants considered third-generation plasminogen activators. TNK-t-PA is one bioengineered variant of t-PA. Another third-generation plasminogen activator is reteplase (r-PA). Like TNK-t-PA, it is a variant of t-PA that has been developed to establish a more rapid, complete, and stable coronary artery patency, thus promising reduced mortality. Both r-PA and TNK-t-PA are effective when given as bolus therapy. This feature may facilitate more rapid treatment as well as decrease overall costs of treatment. New fibrinolytic regimens include potent antiplatelet agents that may improve sustained reperfusion. This review summarizes the latest and often confusing data on the interaction between fibrinolytic therapy and platelets in certain in vitro, animal and clinical scenarios.

AB - Fibrinolytic therapy is sthe established treatment for the management of patients with ST elevation acute myocardial infarction (AMI). Present fibrinolytic regimens have a number of shortcomings, including the failure to produce early and sustained reperfusion, as well as failure to prevent reocclusion in at least some patients. Platelets play an important role in coronary thrombosis responsible for AMI. The effect of coronary fibrinolysis on platelets has been extensively debated in the literature with evidence of both platelet activation and inhibition. Among fibrinolytic agents, tissue plasminogen activator (t-PA) is considered to be the mainstay in the treatment of coronary artery disease. The native t-PA molecule has been modified in an attempt to achieve improved lytic characteristics with less risk of bleeding. The result is a group of mutant t-PA variants considered third-generation plasminogen activators. TNK-t-PA is one bioengineered variant of t-PA. Another third-generation plasminogen activator is reteplase (r-PA). Like TNK-t-PA, it is a variant of t-PA that has been developed to establish a more rapid, complete, and stable coronary artery patency, thus promising reduced mortality. Both r-PA and TNK-t-PA are effective when given as bolus therapy. This feature may facilitate more rapid treatment as well as decrease overall costs of treatment. New fibrinolytic regimens include potent antiplatelet agents that may improve sustained reperfusion. This review summarizes the latest and often confusing data on the interaction between fibrinolytic therapy and platelets in certain in vitro, animal and clinical scenarios.

KW - Alteplase

KW - Platelets

KW - Reteplase

KW - Streptokinase

KW - Tenecteplase

UR - http://www.scopus.com/inward/record.url?scp=0034937230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034937230&partnerID=8YFLogxK

U2 - 10.1159/000047346

DO - 10.1159/000047346

M3 - Article

C2 - 11423707

AN - SCOPUS:0034937230

VL - 95

SP - 55

EP - 60

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 2

ER -